Skip to content

Impact of chemotherapy on muscle composition of breast cancer patients.

The impact of 18 weeks of chemotherapy-treatment with Taxotere/Adriamycin/Cyclophosphamide (TAC) on skeletal muscle composition of female breast cancer patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON25768
Enrollment
13
Registered
2012-05-23
Start date
2012-06-01
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer cachexia Spierverlies bij kanker

Interventions

All interventions will be performed before and after 18 weeks of chemotherapy: 1. Maximal strength assesment
2. Maximal cycling test
3. Muscle biopsy from the vastus lateralis muscle
4. Venous blood sample
5. Dexa scan
6. Questionnaires regarding physical activity, dietary status and quality of life.

Sponsors

Maxima Medisch Centrum, Veldhoven
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Female breast cancer patients; 2. Age between 30-65 years; 3. 18 weeks of chemotherapy treatment with TAC.

Exclusion criteria

Exclusion criteria: 1. Participation in an exercise rehabilitation program during the study; 2. Chronic diseases that influence skeletal muscle characteristics, like type II diabetes mellitus, chronic obstructive pulmonary disease, chronic heart failure; 3. Chronic inflammatory disorders, like rheumatoid arthritis, colitis ulcerosa or Crohn's disease; 4. Musculoskeletal disorders that cause an inability to perform exercise.

Design outcomes

Primary

MeasureTime frame
Changes in muscle mass, measured with dexa scan and fiber cross sectional area in muscle biopsy from the vastus lateralis muscle.

Secondary

MeasureTime frame
1. Changes in muscle strength; 2. Changes in endurance capacity; 3. Changes in markers of systemic inflammation and metabolism; 4. Changes in physical activity, diet and quality of life.

Contacts

Public ContactM. Beelen

Maxima Medisch Centrum De Run 4600

m.beelen@mmc.nl+31 (0)40 8888688

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)